This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ueland, T. Articles by Aukrust, P. Search for Related Content PubMed PubMed Citation Articles by Ueland, T. Articles by Aukrust, P.

Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction

Thor Ueland, BSc^*,,*, Rune Jemtland, PhD, Kristin Godang, BSc, John Kjekshus, MD, PhD, Aina Hognestad, MD^*,||, Torbjørn Omland, MD, PhD^¶, Iain B. Squire, MD^**, Lars Gullestad, MD, PhD^||, Jens Bollerslev, MD, PhD, Kenneth Dickstein, MD, PhD^# and Pål Aukrust, MD, PhD^*,

^* Research Institute for Internal Medicine
Section of Endocrinology
Department of Cardiology
Section of Clinical Immunology and Infectious Diseases, National University Hospital, Oslo, Norway
^|| Department of Cardiology, Baerum Hospital, Baeum, Norway
^¶ Department of Medicine, Akershus University Hospital, Nordbyhagen, Norway
^# University of Bergen, Cardiology Division, Central Hospital in Rogaland, Stavanger, Norway
^** Department of Medicine and Therapeutics, University of Leicester, Leicester, United Kingdom

View larger version (20K): [in a new window]   Figure 1 Plasma osteoprotegerin (OPG) levels during two years' follow-up in relation to randomization status. Shaded area represents 95% confidence interval for healthy age- and gender-matched controls. BL = baseline.

View larger version (19K): [in a new window]   Figure 2 Kaplan-Meier curves showing the cumulative incidence of death during the entire study (median follow-up 27 months), according to the quartiles (Q) of plasma osteoprotegerin at enrollment.

View larger version (21K): [in a new window]   Figure 3 Unadjusted risk ratios for quartiles (Q) of osteoprotegerin at baseline in relation to incidence of angina, nonfatal myocardial infarction (MI), cardiac death, total mortality, or the composite end point (all-cause mortality, stroke, and nonfatal MI). *p < 0.05; p < 0.01; p < 0.001 vs. Q1.

View larger version (20K): [in a new window]   Figure 4 Plasma osteoprotegerin (OPG) levels during two-year follow-up in survivors and non-survivors. *p < 0.01; **p < 0.001 non-survivors versus survivors. Four non-survivors died after the last sampling (two year). Shaded area represents 95% confidence interval for healthy age- and gender-matched controls. BL = baseline.